Key result
Dilated IVC is linked to ~3.2-fold higher risk of adverse outcomes in acute HFpEF.
Why the study?
Few data exist on the assessment of pulmonary artery systolic pressure (PASP) and inferior cava vein (ICV) status, and their prognostic impact, in acute HFpEF.
Does inferior cava vein dilatation predict adverse outcomes in patients with acute heart failure with preserved ejection fraction?
Cohort (n=173)
No
Does inferior cava vein dilatation predict adverse outcomes in patients with acute heart failure with preserved ejection fraction?
Hazard Ratio: 3.22 (95% CI 1.58–6.55)
p-value: p=0.001
In patients with acute HFpEF, echocardiographic assessment of inferior vena cava dilatation provides significant independent prognostic information over isolated elevated pulmonary artery systolic pressure.
May aid risk stratification in acute HFpEF; hypothesis-generating and requires prospective validation before practice change.
Background: Peak tricuspid regurgitation (TR) velocity and inferior cava vein (ICV) distention are two recognized features of increased pulmonary artery pressure (PASP) and right atrial pressure, respectively. Both parameters are related to pulmonary and systemic congestion and adverse outcomes. However, few data exist about the assessment of PASP and ICV in acute patients affected by heart failure with preserved ejection fraction (HFpEF). Thus, we investigated the relationship existing among clinical and echocardiographic features of congestion, and we analyzed the prognostic impact of PASP and ICV in acute HFpEF patients. Methods and Results: We analyzed clinical congestion PASP and ICV value in consecutive patients admitted in our ward by echocardiographic examination using peak Doppler velocity tricuspid regurgitation and ICV diameter and collapse for the assessment of PASP and ICV dimension, respectively. A total of 173 HFpEF patients were included in the analysis. The median age was 81 and median left ventricular ejection fraction (LVEF) was 55% [50–57]. Mean values of PASP was 45 mmHg [35–55] and mean ICV was 22 [20–24] mm. Patients with adverse events during follow-up showed significantly higher values of PASP (50 [35–55] vs. 40 [35–48] mmHg, (p = 0.005) and increased values of ICV (24 [22–25] vs. 22 [20–23] mm, p < 0.001). Multivariable analysis showed prognostic power of ICV dilatation (HR 3.22 [1.58–6.55], p = 0.001) and clinical congestion score ≥ 2 (HR 2.35 [1.12–4.93], p = 0.023), but PASP increase did not reach statistical significance (p = 0.874). The combination of PASP > 40 mmHg and ICV > 21 mm was capable of identifying patients with increased events (45% vs. 20%). Conclusions: ICV dilatation provides additional prognostic information with respect to PASP in patients with acute HFpEF. A combined model adding PASP and ICV assessment to clinical evaluation is a useful tool for predicting HF related events.
No takes yet. Share an insight, caveat, or question.
Ruocco et al. (2023) conducted a cohort in Acute heart failure with preserved ejection fraction (HFpEF) (n=173). Inferior cava vein (ICV) dilatation (>21 mm) vs. ICV ≤ 21 mm was evaluated on Composite of death, re-hospitalization for heart failure, and cardiovascular mortality at 180 days (HR 3.22, 95% CI 1.58-6.55, p=0.001). Inferior cava vein dilatation (>21 mm) was significantly associated with an increased risk of adverse cardiovascular events and hospitalization (HR 3.22) in patients with acute HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: